Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23
United States Fiscal year ends December CIK 0001672619 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Helen Louise Collins
19 Oct 2026
Chief Medical Officer
Sold after exercise
5,000
$38.47
$192.34K
Benjamin Hohl
19 Oct 2026
Chief Financial Officer
Sold after exercise
6,018
$38.48
$231.55K
J. Scott Garland
1 Oct 2026
Director
Sold after exercise
13,000
$46.67
$606.72K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
240
$51.48
$12.36K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
1,844
$50.71
$93.51K
Helen Louise Collins
17 Sep 2026
Chief Medical Officer
Sold after exercise
2,916
$50.03
$145.89K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
289
$51.49
$14.88K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
2,194
$50.72
$111.27K
Benjamin Hohl
17 Sep 2026
Chief Financial Officer
Sold after exercise
3,535
$50.03
$176.85K
Helen Louise Collins
17 Aug 2026
Chief Medical Officer
Sold after exercise
1,100
$59.35
$65.28K
Helen Louise Collins
17 Aug 2026
Chief Medical Officer
Sold after exercise
3,900
$58.37
$227.65K
Mika K Derynck
4 Aug 2026
Director
Sold after exercise
158,795
$60.21
$9.56M
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
63
$53.92
$3.40K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
2,184
$53.42
$116.67K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
2,063
$52.39
$108.08K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
459
$51.55
$23.66K
Helen Louise Collins
17 Jul 2026
Chief Medical Officer
Sold after exercise
231
$50.05
$11.56K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
123
$53.87
$6.63K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
2,638
$53.38
$140.82K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
2,564
$52.32
$134.14K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
369
$51.48
$19.00K
Benjamin Hohl
17 Jul 2026
Chief Financial Officer
Sold after exercise
324
$49.97
$16.19K
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
1,133
$44.74
$50.69K
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
2,599
$43.87
$114.02K
Helen Louise Collins
17 Jun 2026
Chief Medical Officer
Sold after exercise
1,268
$42.83
$54.30K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
1,238
$44.75
$55.40K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
3,401
$43.86
$149.18K
Benjamin Hohl
17 Jun 2026
Chief Financial Officer
Sold after exercise
1,379
$42.79
$59.00K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
223
$41.21
$9.19K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
1,302
$40.25
$52.40K
Helen Louise Collins
18 May 2026
Chief Medical Officer
Sold after exercise
3,475
$39.53
$137.38K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
2,441
$48.06
$117.30K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
2,419
$47.39
$114.64K
Helen Louise Collins
17 Apr 2026
Chief Medical Officer
Sold after exercise
140
$45.81
$6.41K
Helen Louise Collins
25 Mar 2026
Chief Medical Officer
Sold after exercise
40,000
$35.10
$1.40M
Helen Louise Collins
17 Mar 2026
Chief Medical Officer
Sold after exercise
5,000
$27.76
$138.80K
Helen Louise Collins
10 Mar 2026
Chief Medical Officer
Sold after exercise
10,129
$30.19
$305.83K
Helen Louise Collins
9 Mar 2026
Chief Medical Officer
Sold after exercise
29,871
$30.02
$896.81K
Helen Louise Collins
17 Feb 2026
Chief Medical Officer
Sold after exercise
45,000
$26.17
$1.18M

What was left out

Form 4 filings counted 52
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 30
Sales straight out of an exercise 39
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 482,634
History held since 16 Mar 2020